Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 9/20 | 0.37 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073246 | 0.81 | HRH3 (0.51) | HRH3PTGS2CA12CA2CA9 | |
| SCHEMBL4065720 | 0.77 | HRH3 (0.53) | HRH3PTGS2CA12CA2CA9 | |
| SCHEMBL28111302 | 0.77 | KMT2A (0.56) | HRH3PTGS2CA12CA2CA9 | |
| SCHEMBL6295109 | 0.75 | HRH3 (0.58) | HRH3PTGS2CA12CA2CA9 | |
| SCHEMBL4073241 | 0.71 | HRH3 (0.48) | HRH3PTGS2CA12CA2CA9 | |
| SCHEMBL6295031 | 0.71 | HRH3 (0.64) | HRH3NR1H2 | |
| SCHEMBL4063701 | 0.68 | HRH3 (0.68) | HRH3NR1H2 | |
| SCHEMBL4058799 | 0.68 | HRH3 (0.85) | HRH3 | |
| SCHEMBL4061699 | 0.68 | HRH3 (1.00) | HRH3 | |
| SCHEMBL29185292 | 0.68 | NR4A2 (0.42) | NR4A2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268421-B1 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-6872834-B2 | Phenyl-substituted indoles and indazoles | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1268421-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074773-A2 | PHENYL-SUBSTITUTED INDOLES AS HISTAMINE H3-RECEPTOR ANTAGONISTS | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006928-A1 | Phenyl-substituted indoles and indazoles | IDO1, IDO2, AADAC | HRH3 1173/4885PTGS2 939/4885NR4A2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.